SY08-3 Recent advances in targeted therapy for B-cell malignancies

Abstract

The introduction of rituximab has represented a major milestone in the treatment of B-cell malignancies. However, a proportion of patients eventually will relapse or will be primary refractory. In this clinical setting, targeting new surface antigens either using monospecific antibodies or drug immunoconjugates are appealing treatment approaches. Additionally, exploiting cytotoxic T-cells using bispecific antibodies has been considered as a disruptive therapeutic strategy for lymphomas.